Synthesis, crystal structure and anticancer activity of a novel ternary copper(II) complex with Schiff base derived from 2-amino-4-fluorobenzoic acid and salicylaldehyde

Inorganic Chemistry Communications

Volumn 50, Issue , 2014, Pages 35-41

  Li, Xin ^a   Bi, Cai Feng ^a   Fan, Yu Hua ^a   Zhang, Xia ^a   Meng, Xiang Min ^a   Cui, Lian Sheng ^a  

^a OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Anticancer activity; Copper(II) complex; Crystal structure; Proteasome inhibitor; Schiff base

Indexed keywords

EID: 84908510532     PISSN: 13877003     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.inoche.2014.10.014     Document Type: Article

References (33)

1. M.J. Abrams, B.A. Murrer, Metal compounds in cancer therapy and diagnosis, Science 261 (1993) 725-730.
2. M.A. Neelakantan, M. Esakkiammal, S.S. Mariappan, J. Dharmaraja, T. Jeyakumar, Synthesis, characterization and biocidal activities of some Schiff base metal complexes, Indian J. Pharm. Sci. 72 (2010) 216-222.
3. T. Hirohama, Y. Kuranuki, E. Ebina, T. Sugizaki, H. Arii, M. Chikira, Copper(II) complexes of 1,10-phenanthroline-derived ligands: studies on DNA binding properties and nuclease activity, J. Inorg. Biochem. 99 (2005) 1205-1219.
4. F.L. Yin, J.J. Zhu, J. Hao, J.R. Cui, J.J. Yang, Synthesis, characterization, crystal structure and antitumor activities of a novel demethylcantharidato bridged copper(II) phenanthroline complex, Sci. China Chem. 56 (2013) 481-489.
5. J.A. Dams, Potential for proteasome inhibition in the treatment of cancer, Drug Discov. Today 8 (2003) 307-315.
6. J.B. Almond, G.M. Cohen, The proteasome: a novel target for cancer chemotherapy, Leukemia 16 (2002) 433-443.
7. R.Z. Orlowski, T.E. Stinchcombe, B.S. Mitchell, Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies, J. Clin. Oncol. 20 (2002) 4420-4427.
8. J. Adams, V.J. Palombella, E.A. Sausville, Proteasome inhibitors: a novel class of potent and effective antitumor agents, Cancer Res. 59 (1999) 2615-2622.
9. M. Hochstrasser, Ubiquitin proteasome and the regulation of intracellular protein degradation, Curr. Opin. Cell Biol. 7 (1995) 215-223.
10. A. Ciechanover, The ubiquitin-proteasome proteolytic pathway, Cell 79 (1994) 13-21.
11. A.L. Goldberg, Functions of the proteasome: the lysis at the end of the tunnel, Science 268 (1995) 522-523.
12. E. Seemuller, A. Lupas, D. Stock, J. Lowe, R. Huber, W. Baumeister, Proteasome from Thermoplasma acidophilum: a threonine protease, Science 268 (1995) 579-582.
13. H.J. Yang, D. Chen, Q.C. Cui, X. Yuan, Q.P. Dou, Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine", is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice, Cancer Res. 66 (2006) 4758-4765.
14. M. Freeza, S. Schmitt, Q.P. Dou, Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy, Curr. Top. Med. Chem. 11 (2011) 2888-2905.
15. 1H NMR (DMSO-d6, 600 MHz) δ(ppm): 6.885 (d, 1H), 7.071 (d, 1H), 7.235 (d, 1H), 7.354 (d, 1H), 7.506 (d, 1H), 7.541 (d, 1H), 7.747 (s, 1H), 7.835 (s,1H), 8.362 (s, 1H), 11.107 (s, 1H).
16. 1H NMR (DMSO-d6, 600 MHz) δ(ppm): 6.795 (d, 1H), 7.068 (d, 1H), 7.186 (d, 1H), 7.327 (d, 1H), 7.497 (d, 1H), 7. 527 (d, 1H), 7.794 (s, 1H) 8.062 (s, 1H).
17. 2) to convergence.
18. G.M. Sheldrick, SHELXTL-97, Program for Crystal Structure Refinement, University of Göttingen, Germany, 1997.
19. X. Li, C.F. Bi, Y.H. Fan, X. Zhang, X.D. Wei, X.M. Meng, Synthesis, characterization, DNA binding and cleavage properties of a ternary copper(II) Schiff base complex, Transit. Met. Chem. 39 (2014) 577-584.
20. 2. The cells were harvested, lysed and supernatants were collected as whole cell extracts used for western blot analysis.
21. MDA-MB-231 cells were seeded in triplicate in a 96-well plate and incubated at 37°C until 70-80% con fl uent, then treated with the indicated concentration of the complex and the ligand for 24 h. Media was then removed and MTT solution (1 mg/ml) was added followed by a 2 h incubation period. MTT was then removed and 100 μl DMSO added to dissolve the metabolized MTT product, followed by measuring the absorbance values on a Victor 3 multi-label plate reader (PerkinElmer Wellesley, MA).
22. K.G. Daniel, D. Chen, S. Orlu, Q.C. Cui, F.R. Miller, Q.P. Dou, Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells, Breast Cancer Res. 7 (2005) 897-908.
23. A. Kellett, M. O'Connor, M. McCann, M. McNamara, P. Lynch, G. Rosair, Bisphenanthroline copper(II) phthalate complexes are potent in vitro antitumour agents with 'self-activating' metallo-nuclease and DNA binding properties, Dalton Trans. 40 (2011) 1024-1027.
24. 2, J. Inorg. Biochem. 98 (2004) 1271-1283.
25. 2, J. Inorg. Biochem. 99 (2005) 467-476.
26. MDA-MB-231 cells were treated as indicated, lysed and protein concentrations measured by the Bio-Rad Protein Assay (Bio-Rad Hercules, CA). Whole cell extracts (10 μg) were incubated for 2 h at 37°C in 100 μl of assay buffer (20 mM Tris-HCl, pH 7.5) with 20 μM fluorogenic peptide substrate Suc-LLVY-AMC. Proteasomal CT-like activity was measured using the Wallac Victor 3 Multi-label Counter with an excitation filter of 365 nm and emission filter of 460 nm.
27. Proteins (30 μg) from whole cell extracts were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane, followed by visualization with an enhanced chemiluminescence reagent (Denville Scientific Metuchen, NJ).
28. D. Chen, M.S. Chen, Q.C. Cui, H. Yang, Q.P. Dou, Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells, Front. Biosci. 12 (2007) 1935-1945.
29. S. Nam, D.M. Smith, Q.P. Dou, Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo, J. Biol. Chem. 16 (2001) 13322-13330.
30. B. An, R.H. Goldfarb, R. Siman, Q.P. Dou, Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts, Cell Death Differ. 5 (1998) 1062-1075.
31. H.C. Drexler, Activation of the cell death program by inhibition of proteasome function, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 855-860.
32. U.G. Lopes, P. Erhardt, R. Yao, G.M. Cooper, p53-Dependent induction of apoptosis by proteasome inhibitors, J. Biol. Chem. 272 (1997) 12893-12896.
33. Cellular morphology changes were observed using a Zeiss (Thornwood, NY) Axiovert 25 microscope with phase contrast.